Bispecific Monoclonal Antibodies
- Name
- Bispecific Monoclonal Antibodies
- Accession Number
- DBCAT005664
- Description
A monoclonal antibody that can simultaneously bind to two different types of antigen or epitopes.
- Drugs
Drug Drug Description Amivantamab An EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation. Catumaxomab For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label]. Teclistamab A bispecific B-cell maturation antigen (BCMA)-directed CD3 T cell engager used to treat relapsed and refractory multiple myeloma in adults as monotherapy. Glofitamab A bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Epcoritamab A bispecific CD20-directed CD3 T-cell engager used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults. Talquetamab A bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. Elranatamab A bispecific antibody used to treat adults with relapsed or refractory multiple myeloma. - Drugs & Drug Targets